Clinical trial

Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis

Name
2021-06-clinical study
Description
The goal of this clinical trial is to evaluate the immediate analgesic effect and patients' evaluation of the treatment of cheek acupuncture in patients with acute gouty arthritis. The main question it aims to answer are: Does cheek acupuncture has immediate pain relief effects on patients with acute gouty arthritis. Participants will received cheek acupuncture for 30 mins. If there is a comparison group: Researchers will compare etoricoxib group to see if cheek acupuncture is superior to etoricoxib for improvement of acute pain in subjects with acute gouty arthritis.
Trial arms
Trial start
2023-09-01
Estimated PCD
2023-12-31
Trial end
2023-12-31
Status
Recruiting
Treatment
cheek acupuncture
Based on the theory of holography and the theory of the Great Sanjiao, the acupoints were chosen under the guidance of the foundation of cheek acupuncture, selecting bilateral Sanjiao acupoints, bilateral head acupoints, foot and ankle acupoints on the affected side, and matching acupuncture points for local strengthening of the foot and ankle acupuncture points, using the triangular needle strengthening method. The treatment was performed with the patient lying on his back in a comfortable position, with routine local disinfection, rapid transdermal needle entry to the acupuncture points, and needle discharge after 30 minutes of needle retention, after which the needle hole was compressed with a cotton ball for a few moments.
Arms:
acupuncture group
Etoricoxib
etoricoxib 120mg
Arms:
etoricoxib
Size
76
Primary endpoint
Visual Analogue Scoring (VAS)
baseline, 0 minute, 30 minutes, 1 hour and 2 hours after the start of treatment
Eligibility criteria
Inclusion Criteria: * Meet the diagnostic criteria for acute gouty arthritis and with attacks in the unilateral ankle or first metatarsophalangeal joint; * Age ≥18 years old and ≤75 years old, regardless of gender; ③ The gouty arthritis attack is within 48h; ④ Without therapy with targeted topical treatment or self-administered medications including colchicine, anti-inflammatory pain medications, hormones, herbs, etc. Agreement to comply with the clinician's treatment plan. Exclusion Criteria: * Pregnant or breast-feeding * Patients with malignant tumors, severe dysfunction of the heart, liver, and kidneys, diabetes mellitus and hypertension * Mental disorders that render the patient unable to understand the nature of the study, its scope, and possible outcomes or unable to follow the doctor's advice * Allergic to the components of the drug in this study * Patients with active peptic ulcers/bleeding, or previous recurrent ulcers/bleeding. * History of asthma, urticaria or allergic reactions induced by taking aspirin or other non-steroidal anti-inflammatory drugs * Congestive heart failure (New York Heart Association \[NYHA\] cardiac function class II-IV)
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 76, 'type': 'ESTIMATED'}}
Updated at
2023-11-09

1 organization

1 product

3 indications

Product
Etoricoxib
Indication
Gout
Indication
Acupuncture
Indication
Pain